Suggested remit: To appraise the clinical and cost effectiveness of itopride hydrochloride within its marketing authorisation for treating gastrointestinal symptoms of functional non-ulcer dyspepsia.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Decision publication date:
- 04 February 2026
- Prioritisation programme:
- Medicines evaluation
- Rationale:
Criteria within the (VPAG) met as a new active substance.
- Process:
- STA Standard
- ID number:
- 6745
Project Team
- Project lead
- scopingta@nice.org.uk
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 14 July 2026 - 11 August 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6745 |
| 14 July 2026 | Deferred. Scoping commencing |
| 14 July 2026 | In progress. Scoping commencing |
| 04 February 2026 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual